Shuchi Nahar's Weekend Blog!

Scope for Ready to Eat Food (Market size, Major Players, Changing Patterns)-Great opportunities Ahead Twitter Handle: @shuchi_nahar Global Ready To Eat Industry Globally, the demand for Ready-to-Eat (RTE) food has grown significantly and is expected to reach US $172 billion by the end of 20231. Changing food habits, lack of time and easy accessibility to various food groups have generated a huge demand for these products. Driven by high disposable incomes, ease of use, busy lifestyle, and better nutritive content, consumers globally are relying more on Ready - to - Eat food. Ready to Eat Industry –Market size & Growth The global ready meals market size was valued at USD 159.15 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 5.5% from 2020 to 2027 . Shifting consumers’ food preferences towards ready-to-eat food products owing to the busy lifestyle of working individuals as well as hectic work schedules of college grads and students are expect

Jubilant Life Sciences-Unseen Opportunities Ahead (COVID-19 V accine manufacturing, Demerger of business inline) Twitter Handle: @shuchi_nahar Company Overview Incorporated in 1978, Jubilant Life Sciences (JLS; formerly Jubilant Organosys), is a mid-sized integrated chemical turned pharmaceuticals player. It started as a full-fledged chemical a company by entering the vinyl acetate monomer (VAM) business in 1983.  Broadly, the company operates through two business segments - pharmaceuticals (62% of the turnover) and life science ingredients (35% of turnover).  The pharmaceuticals segment consists of sub-segments like  1) generics  2) specialty pharma - radio pharma and allergy therapy products and  3) CDMO - contract manufacturing (CMO) of sterile injectables and API. In November 2020, Jubilant Life entered into a strategic partnership with SOFIE Biosciences, Inc. (SOFIE), US. Under the terms of the agreement, Jubilant will acquire 25% of equity holding for a cash consideration of

“Practitioners’ Insights: Understanding Pharma” Shuchi.P.Nahar India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50% of global demand for various vaccines,  40% of generic demand in the US and 25 % of all medicine in UK. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 % of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are by Indian pharmaceutical firms. The global pharmaceutical market is expected to exceed $1.5 trillion by 2023 growing at a 3−6% compound annual growth rate over the next five years. The key drivers of growth will continue to be the United States and emerging markets with 4−7% and 5–8% compound annual growth, respectively. The global outlook for medicine use and spendi